Site Editor

Rebecca Olin, MD, MS


FDA Brief: New CAR T-Cell Therapy Granted Fast Track Designation in AML

By: Lauren Velentzas
Posted: Wednesday, April 13, 2022

The biopharmaceutical company Precigen recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PRGN-3006—an autologous, gene-edited T-cell therapy that targets CD33—for treatment of patients with relapsed or refractory acute myeloid leukemia (AML). The therapy uses the company’s UltraCAR-T therapeutic platform to express a chimeric antigen receptor (CAR) specifically targeting CD33, membrane-bound interleukin-15 for enhanced in vivo expansion and persistence, and a “kill” switch to conditionally eliminate CAR T cells.

The FDA previously granted PRGN-3006 Orphan Drug designation. The Fast Track designation comes as PRGN-3006 is being evaluated as part of a single-center phase I/IB dose-escalation/dose-expansion study. The study will enroll adults with relapsed or refractory AML receiving a single-therapy dose with or without prior lymphodepletion. Interim results from the study were presented at the 2021 American Society of Hematology Annual Meeting & Exposition. These results showed a 50% overall response rate among the first six patients in the lymphodepletion cohort and no dose-limiting toxicities. Of 15 patients, 1 experienced grade 3 cytokine-release syndrome.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.